Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR3 | P32745 | 1/20 | 0.53 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.42 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.42 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26439273 | 0.91 | SSTR3 (0.53) | SSTR3CALCRLLTA4HECE1MMP3 | |
| SCHEMBL22010347 | 0.91 | SSTR3 (0.51) | SSTR3CALCRLLTA4HECE1MMP3 | |
| SCHEMBL19340304 | 0.89 | SSTR3 (0.51) | SSTR3CALCRLLTA4HECE1MMP3 | |
| SCHEMBL17706674 | 0.88 | SSTR3 (0.55) | SSTR3CALCRLLTA4HECE1MMP3 | |
| SCHEMBL14821040 | 0.88 | SSTR3 (0.55) | SSTR3CALCRLLTA4HECE1MMP3 | |
| SCHEMBL18494988 | 0.88 | SSTR3 (0.55) | SSTR3CALCRLLTA4HECE1MMP3 | |
| SCHEMBL14872058 | 0.88 | SSTR3 (0.55) | SSTR3CALCRLLTA4HECE1MMP3 | |
| SCHEMBL16479322 | 0.87 | SSTR3 (0.53) | SSTR3CALCRLLTA4HMMP3SIRT1 | |
| SCHEMBL22096459 | 0.87 | SSTR3 (0.51) | SSTR3CALCRLLTA4HMMP3SIRT1 | |
| SCHEMBL24101424 | 0.85 | SSTR3 (0.54) | SSTR3CALCRLLTA4HMMP3PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11779650-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-10-10 | — | — | US | disclosed |
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11702473-B2 | Site-specific antibody-drug conjugates | MEDIMMUNE LIMITED (GB) | 2023-07-18 | — | — | US | disclosed |
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | MEDIMMUNE LIMITED (GB) | 2023-07-04 | — | — | US | disclosed |
| US-11692043-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | MEDIMMUNE LIMITED (GB) | 2023-07-04 | — | — | US | disclosed |
| US-11572349-B2 | Selective sulfonation of benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220016261-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2022-01-20 | — | — | US | disclosed |
| US-11033634-B2 | Light chain variable regions | ABBVIE STEMCENTRX LLC (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210137940-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2021-05-13 | — | — | US | disclosed |
| US-20210113587-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P. | 2021-04-22 | — | — | US | disclosed |
| US-20170267778-A1 | HUMANIZED ANTI-TN-MUC1 ANTIBODIES AND THEIR CONJUGATES | MEDIMMUNE LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-9764042-B1 | Methods of making DLL3 antibody drug conjugates | ABBVIE STEMCENTRX LLC (US) | 2017-09-19 | — | — | US | disclosed |
| US-9713647-B2 | Pyrrolobenzodiazepines and targeted conjugates | SEATTLE GENETICS, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-9707301-B2 | Pyrrolobenzodiazepines and targeted conjugates | SEATTLE GENETICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9676850-B2 | Anti SEZ6 antibodies and methods of use | ABBVIE STEMCENTRX LLC (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170143846-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | SPIROGEN LIMITED (GB) | 2017-05-25 | — | — | US | disclosed |
| US-9592240-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9562049-B2 | Pyrrolobenzodiazepines and conjugates thereof | MEDIMMUNE LIMITED (GB) | 2017-02-07 | — | — | US | disclosed |
| US-9555125-B2 | Benzodiazepines and conjugates thereof | IMMUNOGEN, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20110256157-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | SPIROGEN LIMITED (GB) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690918-B2 | Pyrrolobenzodiazepine-anti-CD22 antibody conjugates | CD22, CD2, CD2BP2 | SSTR3 2651/4885CALCRL 3676/4885LTA4H 3222/4885 |
| US-20170143846-A1 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES | QDPR, SBDS, DNPEP | SSTR3 1796/4885CALCRL 4710/4885LTA4H 2114/4885 |
| US-11779650-B2 | Pyrrolobenzodiazepine-antibody conjugates | IL2RA, CD4, IL2 | SSTR3 2193/4885CALCRL 3939/4885LTA4H 2766/4885 |
| US-11033634-B2 | Light chain variable regions | IGLV6-57, FCGR2A, FCGR3B | SSTR3 3114/4885CALCRL 3003/4885LTA4H 2174/4885 |
| US-20210113587-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | CD47, CD4, IL2RA | SSTR3 1751/4885CALCRL 3718/4885LTA4H 1762/4885 |
| US-20110256157-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | HDAC10, PBDC1, PDCD10 | SSTR3 2455/4885CALCRL 4837/4885LTA4H 4219/4885 |
| US-20210137940-A1 | PYRROLOBENZODIAZEPINE-ANTI-PSMA ANTIBODY CONJUGATES | PSMA2, PSMA7, FOLH1 | SSTR3 883/4885CALCRL 2461/4885LTA4H 3602/4885 |
| US-11572349-B2 | Selective sulfonation of benzodiazepine derivatives | GABRA2, GABRA4, GABRA1 | SSTR3 1428/4885CALCRL 3719/4885LTA4H 3985/4885 |
| US-20170267778-A1 | HUMANIZED ANTI-TN-MUC1 ANTIBODIES AND THEIR CONJUGATES | MUC1, CD44, VIM | SSTR3 484/4885CALCRL 3186/4885LTA4H 1668/4885 |
| US-11771775-B2 | Pyrrolobenzodiazepine-antibody conjugates | CD79B, BCL6B, BCL6 | SSTR3 1982/4885CALCRL 4405/4885LTA4H 4384/4885 |
| US-11702473-B2 | Site-specific antibody-drug conjugates | SBDS, DCTD, DRD1 | SSTR3 2484/4885CALCRL 4871/4885LTA4H 2319/4885 |
| US-20220016261-A1 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES | PDCD10, CD79B, SBDS | SSTR3 1982/4885CALCRL 4602/4885LTA4H 3609/4885 |
| US-11692043-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | DNPEP, LNPEP, VIP | SSTR3 228/4885CALCRL 1443/4885LTA4H 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.